submit CrossRef Open Access Subscribe New Journal Ideal

Click on image to enlarge

International Journal of Translational Science Journal discontinued 2017

Editors-in-Chief:
Pranela Rameshwar, Rutgers University, USA
Nicholas M. Ponzio, Rutgers University, USA


ISSN: 2246-8765 (Online Version)
Vol: 2016   Issue: 1

Published In:   January 2016

Publication Frequency: Continuous Article Publication


Search Available Volume and Issue for International Journal of Translational Science Journal discontinued 2017


Robin L. Smith, MD, MBA
Chairman of the Board President

Dr. Robin L. Smith is a leading global thought leader in the regenerative medicine industry, one of the fastest growing segments of modern-day medicine.

With an M.D. from Yale University and an M.B.A. from the Wharton School of Business, Dr. Smith is the former CEO of the NeoStem family of companies, which she led from 2006 to 2015 and established as one of the preeminent healthcare brands focused on the development of cellular therapies. While leading NeoStem, Dr. Smith raised over $200 million, completing six acquisitions and one divestiture. Notably, she helped pioneer the company's innovative business model, combining proprietary cell therapy development with a successful contract development and manufacturing organization, which provides these services broadly to companies working in the regenerative medicine industry. The company has won an array of industry awards and business recognition during her tenure, including a #1 ranking in the Tri-State region (for two years in a row), and #11 nationally, on Deloitte's Technology Fast 500™, and Frost & Sullivan's North American Cell Therapeutics Technology Innovation Leadership Award.

Dr. Smith has an extensive and diversified background in healthcare, sales and marketing, business development and management. Her previous experience includes serving as President and Chief Executive Officer of IP2M, a multi-platform media company specializing in healthcare, in which under her leadership, the company was selected as being one of the 10 fastest growing technology companies in Houston.

In 2008, Dr. Smith founded The Stem For Life Foundation (SFLF), a nonpartisan, 501(c)3 educational organization devoted to fostering global awareness of the potential for regenerative medicine to treat and cure a range of deadly diseases and debilitating medical conditions, as opposed to merely treating their symptoms. In 2010, in order to bring the charity's mission to a global audience, Dr. Smith forged a historic, first-of-its-kind partnership with The Vatican. As part of this relationship, The Vatican and SFLF collaborate to create high-profile initiatives that help catalyze interest and development of cellular therapies that could ultimately reduce human suffering on a global scale. Hundreds of the world's leading scientists, doctors, ethicists, and leaders of faith and government attended The Vatican's first and second Regenerative Medicine Conferences, which were held within The Vatican in 2011 and 2013 respectively, and broadcast to global audiences. The next conference will be held in April 2016 and will focus on the use of cellular therapies to treat rare genetic diseases, cancer, diabetes and medical conditions associated with aging, while having a unique emphasis on marginalized populations.

In 2016, Dr. Smith expanded the foundation to broaden the scope and become an entity under the Cura Foundation, a global charitable organization which stands as the parent-entity of SFLF and seeks to catalyze funding for the advancement of a wide array of cellular therapies, whether immunotherapies, adult stem cell treatments, gene therapies, technology or emerging cell-based therapies that enhance cellular health and longevity.

Dr. Smith is well known as a thought leader in regenerative medicine and maintains a regular column on these topics for The Huffington Post. She is a winner of the 2014 Brava! Award, which recognizes top women business leaders in the Greater New York area. She was also a finalist for the 2014 EY Entrepreneur Of The Year award for the New York area, recognizing entrepreneurs who demonstrate excellence and success in the areas of innovation, financial performance and personal commitment to their businesses and communities.

In addition, Dr. Smith has extensive experience serving in executive and board level capacities for various medical enterprises and healthcare-based entities. She currently serves on the Board of Directors of Signal Genetics (NASDAQ: SGNL). In mid-2015, she joined the boards of MYnd Analytics and BioXCell. She also serves on the Board of Directors of the Science and Faith STOQ Foundation in Rome, as well as on the Capital Formation Committee of the Alliance for Regenerative Medicine. She previously served on the Board of Trustees of the NYU Langone Medical Center and is a past Chairman of the Board of Directors for the New York University Hospital for Joint Diseases.

As a business leader, entrepreneur, doctor and philanthropist, Dr. Smith is uniquely positioned to lead the global healthcare industry into the cellular future, where the cells of our bodies will stand as the foundation for a wide array of cures.

River Publishers: International Journal of Translational Science <sup><font color=#f91b02>Journal discontinued 2017</font></sup>